Pasar al contenido principal

MODULACION DE LOS CANALES DE CALCIO OPERADOS POR DEPOSITOS Y SEÑAL DE CALCIO EN CANCER Y ENVEJECIMIENTO NEURONAL

PID2021-125909OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 Viroporin E Induces Ca2+ Release and Neuron Cell Death in Primary Cultures of Rat Hippocampal Cells Aged In Vitro

  • López-Vázquez, Sara
  • Villalobos, Carlos
  • Núñez, Lucía
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The COVID-19 pandemic was caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which may lead to serious respiratory, vascular and neurological dysfunctions. The SARS-CoV-2 envelope protein (E protein) is a structural viroporin able to form ion channels in cell membranes, which is critical for viral replication. However, its effects in primary neurons have not been addressed. Here we used fluorescence microscopy and calcium imaging to study SARS-CoV-2 viroporin E localization and the effects on neuron damage and intracellular Ca2+ homeostasis in a model of rat hippocampal neurons aged in vitro. We found that the E protein quickly enters hippocampal neurons and colocalizes with the endoplasmic reticulum (ER) in both short-term (6–8 days in vitro, DIV) and long-term (20–22 DIV) cultures resembling young and aged neurons, respectively. Strikingly, E protein treatment induces apoptosis in aged neurons but not in young neurons. The E protein induces variable increases in cytosolic Ca2+ concentration in hippocampal neurons. Ca2+ responses to the E protein are due to Ca2+ release from intracellular stores at the ER. Moreover, E protein-induced Ca2+ release is very small in young neurons and increases dramatically in aged neurons, consistent with the enhanced Ca2+ store content in aged neurons. We conclude that the SARS-CoV-2 E protein quickly translocates to ER endomembranes of rat hippocampal neurons where it releases Ca2+, probably acting like a viroporin, thus producing Ca2+ store depletion and neuron apoptosis in aged neurons and likely contributing to neurological damage in COVID-19 patients., This work has been supported by Ministerio de Ciencia, Innovación y Universidades, Spain (Grants Refs. PID2021-125909OB-100 and RTI2018-099298-B-100), Junta de Castilla y León, Spain (Grants # VA294P18, CA9751 and the IBGM Excellence grant Ref. CCVC8485). S.L.-V. was supported by a predoctoral fellowship from Junta de Castilla y León, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitoception, or transfer of normal cell mitochondria to cancer cells, reverses remodeling of store-operated Ca2+ entry in tumor cells

  • Feijóo, Verónica
  • Tajada, Sendoa
  • Méndez-Mena, Alejandra
  • Núñez, Lucía
  • Villalobos, Carlos
Most cancer cells show the Warburg effect, the rewiring of aerobic metabolism to glycolysis due to defective mitochondrial ATP synthesis. As a consequence, tumor cells display enhanced mitochondrial potential (∆Ψ), the driving force for mitochondrial Ca2+ uptake. Mitochondria control the Ca2+-dependent inactivation of store-operated channels (SOCs), leading to enhanced and sustained store-operated Ca2+ entry (SOCE) involved in cancer hallmarks. We asked here whether the transfer of mitochondria (mitoception) from normal cells to tumor cells may reverse SOCE remodeling in cancer cells. For this end, we labeled mitochondria in normal NCM460 human colonic cells, isolated them and transferred them to tumor HT29 cells. We tested the viability and efficiency of mitoception using flow cytometry and confocal microscopy, as well as calcium imaging to investigate the effects of mitoception on SOCE. Our results show that mitoception of tumor HT29 cells with normal mitochondria restores a low ∆Ψ and SOCE. Conversely, self-mitoception of tumor HT29 cells with tumor cell mitochondria increases further ∆Ψ and SOCE, thus excluding the possibility that effects of mitoception are due to increased mitochondrial mass. Strikingly, mitoception of normal NCM460 cells with tumor cell mitochondria has no effects on either ∆Ψ or SOCE. These results are consistent with the previous proposal that transformed mitochondria may modulate SOC channels involved in SOCE. Further research is warranted to test whether mitoception of cancer cells with normal mitochondria may reverse Ca2+ remodeling associated to cancer., This work has been supported by Ministerio de Ciencia, Innovación y Universidades, Spain (Grants Refs. PID2021-125909OB-100 and RTI2018-099298-B-100) and the IBGM Excellence grant Ref. CCVC8485 from regional government of Junta de Castilla y León, Spain. VF was supported by a predoctoral fellowship from Junta de Castilla y León, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cell-based regenerative interventions in Parkinson's disease: Overcoming pharmacological limitations

  • Padilla, Ana Lizeth
  • Lanciego, José Luis
  • Vila, Miquel
  • Castro Soubriet, Fernando de
  • Pozo, David
  • Rodríguez de Fonseca, Fernando
  • Serrano, Antonia
  • Sáez-Valero, Javier
  • Núñez, Lucía
  • Villalobos, Carlos
  • Tapias, Víctor
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons and the pathological aggregation of α-synuclein. While current pharmacological therapies provide symptomatic relief, they do not halt or reverse disease progression. Cell-based regenerative strategies have emerged as promising approaches to restore DA function and target the complex, multifactorial pathophysiology of PD. This review critically examines current approaches, including transplantation of fetal ventral mesencephalic tissue, pluripotent stem cell-derived midbrain DA progenitors, and in vivo reprogramming of endogenous cells. In addition, supportive cell types, such as mesenchymal stromal cells and carotid body glomus cells, provide neuroprotective and immunomodulatory effects via paracrine signaling. We summarize preclinical and clinical evidence on graft survival, integration, and functional recovery, and discuss key determinants of therapeutic efficacy, including mitochondrial function and bioenergetic integrity, immune compatibility, and biomaterial scaffolding. Despite significant progress, major challenges remain regarding long-term efficacy, graft standardization, and host-graft interactions. Ongoing translational advances are poised to drive the development of disease-modifying cell therapies capable of delivering durable clinical benefits and improving long-term outcomes in PD., This work was supported by the Aligning Science Across Parkinson's (#ASAP-020505, USA) through the Michael J. Fox Foundation for Parkinson's Research (MJFF), Ministerio de Ciencia, Innovación y Universidades y Agencia Estatal de Investigación (MICIN/AEI, #PID2020-120308RB, Spain), CiberNed Intramural Collaborative Projects (#PI2020/09, Spain) and Fundación Mutua Madrileña de Investigación Médica (#FMM2020, Spain) to José L. Lanciego; Aligning Science Across Parkinson's (#ASAP-020505, USA) through the MJFF (USA), MICIN/AEI (#PID2020-116339RB-I00, Spain) to Miquel Vila; MICIN/AEI (#PID2022-143110OB-100, Spain), Fundación Ramón Areces (#CIVP19A5917, Spain), Fundación Merck Salud (2023, Spain) and Fundación Grupo de Afectados por Esclerosis Multiple (GAEM, #050601240006, Spain) in collaboration with research networks #RED2022-134081-T and #RED2022-134425-T to Fernando de Castro; MICIN/AEI (#PI22/00427 and #PI20/01399, Spain) and European Regional Development Funds-European Union (ERDF-EU) to Fernando Rodríguez de Fonseca and Antonia Serrano; MICIN/AEI (#RTI2018-098432-BI00), Junta de Andalucía (#PI-232-2022 and #CTS-677), Fundació Catalana d’ELA Miquel Valls (2022, Spain), Fundación Juntos contra la ELA (2023, Spain) to David Pozo; Fondo de Investigaciones Sanitarias (#PI22/01329, Spain), Fondo Europeo de Desarrollo Regional (FEDER), and Dirección General de Ciencia e Investigación de la Generalitat Valenciana (CIAICO/2024/313, Spain) to Javier Sáez-Valero; Excellence Program from Junta de Castilla y León (#CCVC8485, Spain) and MICIN/AEI (#PID2021-125909OB-100, Spain) to Carlos Villalobos and Lucía Núñez, and Junta de Castilla y León (#VA294P18, Spain) to Lucía Núñez; María Zambrano's Excellence Program from the MICIN/AEI (#CONVREC-2021-278, Spain), University of Valladolid and the Internationalization program of Junta de Castilla y León (#CL-EI-2021-09, Spain) to Victor Tapias., Peer reviewed